Regulatory Roundup: FDA Holds Special Press Briefing Regarding Revocation of Genentech's Avastin
FDA Holds Special Press Briefing Regarding Revocation of Genentech's Avastin.
FDA Commissioner Margaret Hamburg held a special press briefing last week on Genentech’s Avastin drug and its indications for metastatic breast cancer. She announced that the agency is revoking that indication based on FDA follow-up studies which did not show promising results. See related blog and press release.
Recent Videos
Related Content
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Article
Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.
